Featured Research

from universities, journals, and other organizations

Leukemia cells have a remembrance of things past

Date:
April 24, 2012
Source:
Veterinärmedizinische Universität Wien
Summary:
Although people generally talk about “cancer”, it is clear that the disease occurs in a bewildering variety of forms.  Even single groups of cancers, such as those of the white blood cells, may show widely differing properties.  How do the various cancers arise and what factors determine their progression?  Clues to these two issues, at least for leukemias, have now been provided.

Although people generally talk about “cancer”, it is clear that the disease occurs in a bewildering variety of forms.  Even single groups of cancers, such as those of the white blood cells, may show widely differing properties.  How do the various cancers arise and what factors determine their progression?  Clues to these two issues, at least for leukemias, have now been provided by Boris Kovacic and colleagues at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna).  The results are published in the current issue of the journal EMBO Molecular Medicine and have extremely important consequences for the treatment of a particularly aggressive type of leukemia.

Related Articles


It is well known that many types of cancer arise as a result of a mutation within a cell and prevailing wisdom has held that the stage of differentiation of this cell determines exactly what form of cancer develops.  For example, it was believed that so-called chronic myeloid leukemia or CML arises from bone marrow stem cells, while a different type of leukemia, known as B-cell acute lymphoid leukemia or B-ALL, results from B-cell precursors.  This belief has been spectacularly refuted by the latest results from Boris Kovacic and colleagues in the Vetmeduni Vienna’s institutes of Animal Breeding and Genetics and of Pharmacology and Toxicology.

The researchers have now shown that both CML and B-ALL arise from the most primordial kind of blood cell (long-term haematopoietic stem cells), although the pathways by which the diseases progress are different.  The usual causes of CML and B-ALL are two highly related versions of the same oncogene, BCR/ABL.  If the primordial blood cells are transformed – or made potentially cancerous – by a particular version of BCR/ABL, for technical reasons termed BCR/ABLp210, the result is chronic myeloid leukemia or CML.  The long-term haematopoietic stem cells remain and act as the dreaded cancer stem cells, or CSCs, which ensure that the disease persists.  Curing chronic myeloid leukemia requires the complete elimination of the CSCs.  However, if the long-term haematopoietic stem cells are transformed by a related version of BCR/ABL, BCR/ABLp185, the result is a highly aggressive form of leukemia, B-ALL.  The finding that B-ALL actually originates from the same stem cells as CML was both unexpected and highly provocative.

Kovacic and colleagues have shown further that B-ALL only develops if the transformed stem cell is exposed to a particular growth factor, interleukin-7.  If interleukin-7 is present (it usually is), the transformed long-term haematopoietic stem cells undergo a differentiation step to CSCs, which in this case correspond to pro-B cells.  If interleukin-7 is absent during the initial phase of transformation, B-ALL cannot develop.

In other words, two distinct types of cell are involved in leukemia development, the primordial cells (also termed the cells of origin of cancer) and the cancer stem cells that cause the disease to progress.  Unless the CSCs are eliminated, fresh cancer cells can arise at any time and the leukemia will recur.  The problem is that current leukemia therapies are not designed to target CSCs.  The primordial CSCs in CML are highly quiescent and thus difficult to target.  In contrast, the CSCs in B-ALL are abundant and have a high turnover rate, which makes them susceptible to treatment.  Treatment of B-ALL may thus succeed in eliminating most CSCs but if even a single cell remains intact it is likely that the patient will relapse, possibly with an even more aggressive form of leukemia.  “A therapy that targets the bulk of tumour cells will not work,” as Kovacic succinctly summarizes his results.  “To treat B-ALL successfully it will be necessary for us to learn much more about the development of the disease.  A combined therapy is required, so future work should aim at developing drugs that target the long-term haematopoietic stem cells from which B-ALL is derived.”


Story Source:

The above story is based on materials provided by Veterinärmedizinische Universität Wien. Note: Materials may be edited for content and length.


Journal Reference:

  1. Boris Kovacic, Andrea Hoelbl, Gabriele Litos, Memetcan Alacakaptan, Christian Schuster, Katrin M. Fischhuber, Marc A. Kerenyi, Gabriele Stengl, Richard Moriggl, Veronika Sexl, Hartmut Beug. Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Molecular Medicine, 2012; 4 (4): 283 DOI: 10.1002/emmm.201100208

Cite This Page:

Veterinärmedizinische Universität Wien. "Leukemia cells have a remembrance of things past." ScienceDaily. ScienceDaily, 24 April 2012. <www.sciencedaily.com/releases/2012/04/120424095653.htm>.
Veterinärmedizinische Universität Wien. (2012, April 24). Leukemia cells have a remembrance of things past. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2012/04/120424095653.htm
Veterinärmedizinische Universität Wien. "Leukemia cells have a remembrance of things past." ScienceDaily. www.sciencedaily.com/releases/2012/04/120424095653.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Diné Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins